An oncolytic virus-based drug JX-594 (also called Pexa-Vec) is highly effective in patients with advanced hepatocellular carcinoma. According to the results of a Phase II clinical trial published online at Nature Medicine journal's website on February 10, 2013, the patients who were given higher (more effective) dose of JX-594 had a median survival of 14.1 months which was twice that seen in the low dose group (6.7 months).
Oncology targets, strategies, cancer drug development and personalized medicine
Showing posts with label liver. Show all posts
Showing posts with label liver. Show all posts
Tuesday, February 19, 2013
Friday, October 15, 2010
Five year anniversary of Nexavar® (sorafenib) approval by FDA
In about two months, five days before Christmas, sorafenib will celebrate five years of approval by the FDA. When it was approved on December 20th, 2005, for advanced Renal Cell Carcinoma (RCC), it was the first (and is so far the only) approved drug to target B-Raf kinase, a signaling component of the MAPK pathway. Since then it has also been approved for Hepatocellular Carcinoma (HCC).
Subscribe to:
Posts (Atom)